Celgene Corporation (CELG)
(Delayed Data from NSDQ)
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Will Pfizer's (PFE) Earnings Beat Estimates Again in Q1?
by Zacks Equity Research
While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and supply shortages in legacy Hospira products will hurt the same.
Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?
by Zacks Equity Research
Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q1.
What's in the Cards for BioMarin (BMRN) in Q1 Earnings?
by Zacks Equity Research
BioMarin (BMRN) is likely to see continued momentum in Kuvan and Vimizim sales. On the call, management is likely to comment on the launch preparation for pegvaliase.
Is a Beat in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
Vertex (VRTX) is expected to beat estimates when it reports its Q1 earnings on Apr 26.
Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus
by Zacks Equity Research
Roche (RHHBY) announces encouraging data on multiple sclerosis (MS) drug Ocrevus which reinforced the efficacy of drug in the long run.
Novartis (NVS) Reports Encouraging Data on MS Candidate
by Zacks Equity Research
Novartis (NVS) announces encouraging results from a phase III study, EXPAND, on siponimod (BAF312) in patients with secondary progressive multiple sclerosis.
Amgen (AMGN) to Report Q1 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva might do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline
by Zacks Equity Research
The FDA approval for Agios' (AGIO) only marketed drug, Idhifa, augurs well for long-term growth. The company is also well on progress track with its lead candidate, ivosidenib, for R/R AML.
Alexion (ALXN) to Acquire Wilson Therapeutics for $855M
by Zacks Equity Research
Alexion (ALXN) announces that the company will acquire Sweden-based Wilson Therapeutics for $855 million, the latest company to join the ongoing acquisitions spree in the biotech sector.
Celgene (CELG) President and COO to Step Down: What's Ahead?
by Zacks Equity Research
Celgene's (CELG) president and chief operating officer, Scott A. Smith, has decided to step down from his position with immediate effect further adding to the company's woes.
Celgene (CELG) Up on Deal With bluebird For CAR-T Candidate
by Zacks Equity Research
Celgene's (CELG) stock was up by 3% after the company announced a co-promotion agreement with bluebird bio for one of its leading CAR-T candidates.
Celgene Loses 17.8% in 3 Months: Time to Reshuffle Portfolio?
by Zacks Equity Research
Things have not been going Celgene's (CELG) way as the company has suffered a series of setbacks. The stock has lost 17.8% in the last three months.
3 Sell-Rated Drug Stocks Investors Should Avoid for Now
by Zacks Equity Research
Despite a fairly upbeat performance of the pharma and biotech sector, caution has to be exercised before choosing a stock for investment as a few drug companies are struggling to revive business.
Biotech Stock RoundUp: ALXN & ARNA Up on Study Data, PRTA Teams Up With Celgene
by Zacks Equity Research
The biotech sector was in focus last week with Alexion gaining on positive data on PNH candidate, Arena surges on ulcerative drug data, Solid Biosciences' stock suffering a crash and Prothena teaming up with Celgene.
Prothena Rallies on Multi-Year Collaboration With Celgene
by Zacks Equity Research
Shares of Prothena (PRTA) surged significantly after the company announced a multi-year collaboration with leading company Celgene to develop new therapies for a broad range of neurodegenerative diseases.
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene
Why Multiple Sclerosis is a Promising but Risky Space?
by Zacks Equity Research
Multiple Sclerosis (MS) is a promising space but risks continue to persist with the recent withdrawal of Zinbryta.
Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck
by Zacks Equity Research
Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck
Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck
by Zacks Equity Research
Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck
Pharmaceutical Industry Outlook - March 2018
by Zacks Equity Research
The year 2017 was rewarding for pharma and biotech stocks, with the sector witnessing some positive developments that led to a much-awaited recovery.
Biotech ETFs Head to Head: XBI vs. IBB.
by Zacks Equity Research
Head-to-head comparison of two Biotech ETFs, XBI and IBB.
Biotech Stock Round Up: Celgene Suffers Setback, Gilead Teams Up with Sangamo
by Zacks Equity Research
The major news in the biotech sector in the last five trading sessions include the FDA's refusal to file letter for Celgene Corporation's (CELG) ozanimod while Gilead Sciences, Inc.'s (GILD) announced an agreement with Sangamo Therapeutics.
Biotech Crushing the Market: Best ETFs & Stocks YTD
by Sweta Killa
The recent developments are fueling growth in the biotech companies, leading to a rally in their share prices and impressive levels of momentum in biotech ETFs.
Celgene (CELG) Down 8.4% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Celgene (CELG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merck to Buy Australian Firm to Boost Immunotherapy Pipeline
by Zacks Equity Research
Merck (MRK) to buy Australian oncolytic immunotherapies maker Viralytics Limited to strengthen its presence in the fast growing immuno-oncology market.